BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of “Moderate Buy” by Brokerages
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-four analysts that are currently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year target price among analysts […]
More Stories
Federal Reserve Leaves Interest Rates Unchanged for 2nd Straight Meeting
By Andrew Moran The Federal Reserve left interest rates unchanged for the second straight meeting, keeping the benchmark policy rate...
Zelenskyy Also Agrees to Limited Russia–Ukraine Cease-Fire in Call With Trump
By Ryan Morgan Ukrainian President Volodymyr Zelenskyy has agreed to a moratorium on attacks on Russia’s energy infrastructure following a...
Federal Judge Declines to Block Firing of US Institute of Peace Leadership
By Stacy Robinson A federal judge on March 19 decided not to block the Trump administration from firing the leadership...
HHS, FDA to Focus on Improving Nutritional Quality of Infant Formula
By Naveen Athrappully The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) are...
Seizert Capital Partners LLC Sells 1,652 Shares of Alphabet Inc. (NASDAQ:GOOGL)
Seizert Capital Partners LLC decreased its position in shares of Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 1.6% during the...
Alphabet Inc. (NASDAQ:GOOGL) Stock Position Trimmed by Symphony Financial Services Inc.
Symphony Financial Services Inc. decreased its position in Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 16.7% in the 4th quarter,...